Spruce Biosciences
South San Francisco, CA · Biotechnology · 200 employees
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company aims to address significant unmet medical needs through innovative treatment solutions. Spruce has a particular focus on rare diseases and is committed to serving patient communities. They are known for their work in enzyme replacement
Funding history
- Funding Round — $50.0M — Oct 2025
- Funding Round — $53.6M — Feb 2023
- Funding Round — $88.0M — Aug 2020
- Funding Round — $88.0M — Feb 2020
- Series series b — $88.0M — Feb 2020
Recent signals
- Feb 03, 2026: Spruce Biosciences Appoints Daven Mody as Senior VP of Regulatory and Quality, Bruno Gagnon as Senior VP of Clinical Development Operations
- Oct 17, 2025: Raised $50.0M
- Oct 15, 2025: SEC 8-K (5.02): On October 15, 2025, Dr. Bali Muralidhar resigned from his position as a member of the board of directors and the compensation committee of Spruce Biosciences, Inc. The resignation was effective immediately. Importantly, Dr. Muralidhar's departure was not due to any disagreements with the Company regarding its operations or policies. This change may impact the Board's dynamics and decision-making processes moving forward.
- Dec 30, 2024: Spruce Biosciences Appoints Kirk Ways as Interim Chief Medical Officer
- Feb 28, 2023: Raised $53.6M
- Aug 14, 2020: Raised $88.0M
- Feb 28, 2020: Raised $88.0M
- Feb 20, 2020: Raised $88.0M in Series series b
See plans & pricing → Track Spruce Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.